Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Virol ; 95(6): e28859, 2023 06.
Article in English | MEDLINE | ID: mdl-37314232

ABSTRACT

Since 1999, Vaccinia virus (VACV) has been described as a causative agent of bovine vaccinia (BV), a zoonotic disease that occurs mainly in rural areas of Brazil. However, the circulation of VACV in urban environments and its associated burden has been poorly explored. Moreover, the current monkeypox (mpox) outbreak has raised questions regarding the immune status of the worldwide population previous vaccinated against smallpox. Hence, we conducted a cross-sectional study to better understand the prevalence of anti-OPV neutralizing antibodies (NA) and related exposure factors in a susceptible urban population of Brazil. A total of 372 individuals were sampled, yielding an overall seroprevalence of 16.9% (CI95% = 13.4-21.1), and antibodies titers ranging from 100 to 800 neutralizing units/mL. The prevalence of NA among individuals potentially vaccinated against smallpox (≥36 years old [yo]) was 24.9% (IC 95% = 19.5-31.2), and among those unvaccinated (<36yo) was 6.7% (IC 95% = 3.7-11.8). Interestingly, contact with horses was pointed out as an exposure factor for the presence of NA, however, the multivariate logistic regression analysis indicated that age ≥36yo and the presence of vaccine take were independently associated with the presence of anti-OPV NA. Our findings suggest that vulnerable populations could be subclinically exposed to VACV in urban areas, drawing attention to alternative routes of zoonotic VACV exposure. Our data is also important for better strategies to mitigate zoonotic OPV infections mainly among vulnerable populations.


Subject(s)
Communicable Diseases , Orthopoxvirus , Smallpox , Horses , Humans , Animals , Cattle , Urban Population , Brazil/epidemiology , Prevalence , Cross-Sectional Studies , Seroepidemiologic Studies , Vaccinia virus , Zoonoses/epidemiology , Antibodies, Neutralizing
2.
Emerg Infect Dis ; 29(3): 664-667, 2023 03.
Article in English | MEDLINE | ID: mdl-36823719

ABSTRACT

We tested coatis (Nasua nasua) living in an urban park near a densely populated area of Brazil and found natural SARS-CoV-2 Zeta variant infections by using quantitative reverse transcription PCR, genomic sequencing, and serologic surveillance. We recommend a One Health strategy to improve surveillance of and response to COVID-19.


Subject(s)
COVID-19 , Procyonidae , Animals , Humans , SARS-CoV-2 , Brazil/epidemiology
3.
Braz J Microbiol ; 53(2): 647-654, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35133637

ABSTRACT

Yellow fever (YF), caused by the yellow fever virus (YFV), is an emerging viral zoonosis that affects humans and non-human primates (NHP). In South America, YF is naturally maintained through enzootic/sylvatic cycles involving NHPs and mosquitoes (Haemagogus and Sabethes). In this study, we retrospectively analyzed wildlife rodents to better understand their role in a potential alternative YF sylvatic cycle. The plaque reduction neutralization test was performed to detect anti-YFV antibodies, while qPCR targeting the NS5 region of flaviviruses and standard PCR targeting the CprM region were applied to detect YFV RNA in tissue and blood samples. YFV was not evidenced in any of the tested samples. These findings provide additional information regarding sylvatic YFV and emphasize the importance of YFV surveillance in wild animals as potential reservoirs/hosts given the well-established enzootic cycle in the studied areas, mainly in the Atlantic Forest.


Subject(s)
Culicidae , Yellow Fever , Animals , Animals, Wild , Brazil/epidemiology , Mosquito Vectors , Retrospective Studies , Rodentia , Yellow Fever/epidemiology , Yellow Fever/veterinary , Yellow fever virus/genetics
4.
Viruses ; 12(11)2020 10 30.
Article in English | MEDLINE | ID: mdl-33143114

ABSTRACT

Yellow fever (YF) is a re-emerging viral zoonosis caused by the Yellow Fever virus (YFV), affecting humans and non-human primates (NHP). YF is endemic in South America and Africa, being considered a burden for public health worldwide despite the availability of an effective vaccine. Acute infectious disease can progress to severe hemorrhagic conditions and has high rates of morbidity and mortality in endemic countries. In 2016, Brazil started experiencing one of the most significant YF epidemics in its history, with lots of deaths being reported in regions that were previously considered free of the disease. Here, we reviewed the historical aspects of YF in Brazil, the epidemiology of the disease, the challenges that remain in Brazil's public health context, the main lessons learned from the recent outbreaks, and our perspective for facing future YF epidemics.


Subject(s)
Epidemics/prevention & control , Public Health , Viral Zoonoses/epidemiology , Yellow Fever/epidemiology , Animals , Brazil/epidemiology , Endemic Diseases/prevention & control , Humans , Primates/virology , Yellow Fever/mortality , Yellow Fever/prevention & control , Yellow Fever Vaccine
5.
Vaccine ; 38(42): 6592-6599, 2020 09 29.
Article in English | MEDLINE | ID: mdl-32788140

ABSTRACT

Yellow Fever (YF) is an acute febrile illness caused by yellow fever virus (YFV), a mosquito-borne flavivirus transmitted to humans and non-human primates. In Brazil, YF is a public health threat and may cause recurrent epidemics, even with the availability of a vaccine. We evaluated the sero-status for YFV in 581 individuals living in a risk area for YF in Brazil. The area presents history of cases and is located in the southeast region of country where outbreaks of YF have been reported since 2016. Through, a PRNT assay, we found 25.8% of individuals lacking YF-neutralizing antibodies. Furthermore, neutralizing antibodies were not detected in 10 individuals with proven vaccination. Our findings reinforce the importance of surveillance systems and the need of an urgent intensification of immunization programs in regions with YFV circulation. Monitoring susceptible individuals that could act as potential disseminators for YFV in risk areas should also be considered.


Subject(s)
Yellow Fever Vaccine , Yellow Fever , Animals , Antibodies, Neutralizing , Brazil/epidemiology , Disease Outbreaks , Humans , Vulnerable Populations , Yellow Fever/epidemiology , Yellow Fever/prevention & control , Yellow fever virus
SELECTION OF CITATIONS
SEARCH DETAIL
...